G. R. Abecasis, A. Auton, L. D. Brooks, M. A. Depristo, R. M. Durbin et al., An integrated map of genetic variation from 1,092 human genomes, Genomes Project Consortium, vol.491, pp.56-65, 2012.

G. Aacr-project and . Consortium, AACR Project GENIE: Powering Precision Medicine through an International Consortium, Cancer Discov, vol.7, pp.818-831, 2017.

N. Alcala, L. Mangiante, N. Le-stang, C. E. Gustafson, S. Boyault et al., Redefining malignant pleural mesothelioma types as a continuum uncovers immune-vascular interactions, EBioMedicine, vol.48, pp.191-202, 2019.

P. Andujar, A. Lacourt, P. Brochard, J. C. Pairon, M. C. Jaurand et al., Five years update on relationships between malignant pleural mesothelioma and exposure to asbestos and other elongated mineral particles, J Toxicol Environ Health B Crit Rev, vol.19, pp.151-172, 2016.
URL : https://hal.archives-ouvertes.fr/inserm-02478603

M. E. Baser, H. Rai, A. J. Wallace, and D. G. Evans, Neurofibromatosis 2 (NF2) and malignant mesothelioma in a man with a constitutional NF2 missense mutation, Fam Cancer, vol.4, pp.321-322, 2005.

Y. Blum, C. Meiller, L. Quetel, N. Elarouci, M. Ayadi et al., Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications, Nat Commun, vol.10, p.1333, 2019.
URL : https://hal.archives-ouvertes.fr/hal-02090279

A. C. Borczuk, J. Pei, R. N. Taub, B. Levy, O. Nahum et al., Genome-wide analysis of abdominal and pleural malignant mesothelioma with DNA arrays reveals both common and distinct regions of copy number alteration, Cancer Biol Ther, vol.17, pp.328-335, 2016.

R. Bueno, E. W. Stawiski, L. D. Goldstein, S. Durinck, A. De-rienzo et al., Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations, Nat Genet, vol.48, pp.407-416, 2016.

J. Calderaro, G. Couchy, S. Imbeaud, G. Amaddeo, E. Letouze et al., Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification, J Hepatol, vol.67, pp.727-738, 2017.

E. Cerami, J. Gao, U. Dogrusoz, B. E. Gross, S. O. Sumer et al., The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data, Cancer Discov, vol.2, pp.401-404, 2012.

A. De-reynies, M. C. Jaurand, A. Renier, G. Couchy, I. Hysi et al., Molecular classification of malignant pleural mesothelioma: identification of a poor prognosis subgroup linked to the epithelial-to-mesenchymal transition, Clin Cancer Res, vol.20, pp.1323-1334, 2014.
URL : https://hal.archives-ouvertes.fr/inserm-02478599

R. Diaz-uriarte, GeneSrF and varSelRF: a web-based tool and R package for gene selection and classification using random forest, BMC Bioinformatics, vol.8, p.328, 2007.

R. Dummer, D. Schadendorf, P. A. Ascierto, A. Arance, C. Dutriaux et al., Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, Lancet Oncol, vol.18, pp.435-445, 2017.

E. Felley-bosco and R. Stahel, Hippo/YAP pathway for targeted therapy, Transl Lung Cancer Res, vol.3, pp.75-83, 2014.

F. Galateau-salle, A. Gilg-soit-ilg, N. Le-stang, P. Brochard, J. C. Pairon et al., , 1998.

, Annales de pathologie, vol.34, pp.51-63

J. Gao, B. A. Aksoy, U. Dogrusoz, G. Dresdner, B. Gross et al., Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal, Sci Signal, vol.6, p.1, 2013.

M. Giovannini, E. Robanus-maandag, M. Van-der-valk, M. Niwa-kawakita, V. Abramowski et al., Conditional biallelic Nf2 mutation in the mouse promotes manifestations of human neurofibromatosis type 2, Genes Dev, vol.14, pp.1617-1630, 2000.

G. Guo, J. Chmielecki, C. Goparaju, A. Heguy, I. Dolgalev et al., Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma, Cancer Res, vol.75, pp.264-269, 2015.

J. Hmeljak, F. Sanchez-vega, K. A. Hoadley, J. Shih, C. Stewart et al., Integrative Molecular Characterization of Malignant Pleural Mesothelioma, Cancer Discov, vol.8, pp.1548-1565, 2018.

H. M. Horlings, S. P. Shah, and D. G. Huntsman, Using Somatic Mutations to Guide Treatment Decisions: Context Matters, JAMA Oncol, vol.1, pp.275-276, 2015.

D. S. Huang, Z. Wang, X. J. He, B. H. Diplas, R. Yang et al., Recurrent TERT promoter mutations identified in a large-scale study of multiple tumour types are associated with increased TERT expression and telomerase activation, Eur J Cancer, vol.51, pp.969-976, 2015.

D. G. Huntsman and M. Ladanyi, The molecular pathology of cancer: from pan-genomics to postgenomics, J Pathol, vol.244, pp.509-511, 2018.

A. N. Husain, T. Colby, N. Ordonez, T. Krausz, R. Attanoos et al., Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group, Arch Pathol Lab Med, vol.137, pp.647-667, 2013.

D. Jean, J. Daubriac, F. Le-pimpec-barthes, F. Galateau-salle, and M. C. Jaurand, Molecular changes in mesothelioma with an impact on prognosis and treatment, Arch Pathol Lab Med, vol.136, pp.277-293, 2012.
URL : https://hal.archives-ouvertes.fr/inserm-02478588

D. Jean, E. Thomas, E. Manie, A. Renier, A. De-reynies et al., Syntenic Relationships between Genomic Profiles of Fiber-Induced Murine and Human Malignant Mesothelioma, Am J Pathol, vol.178, pp.881-894, 2011.
URL : https://hal.archives-ouvertes.fr/inserm-00531343

J. Jongsma, E. Van-montfort, M. Vooijs, J. Zevenhoven, P. Krimpenfort et al., A conditional mouse model for malignant mesothelioma, Cancer Cell, vol.13, pp.261-271, 2008.

M. Lek, K. J. Karczewski, E. V. Minikel, K. E. Samocha, E. Banks et al., Analysis of protein-coding genetic variation in 60,706 humans, Nature, vol.536, pp.285-291, 2016.

H. Li and R. Durbin, Fast and accurate short read alignment with Burrows-Wheeler transform, Bioinformatics, vol.25, pp.1754-1760, 2009.

H. Li, B. Handsaker, A. Wysoker, T. Fennell, J. Ruan et al., The Sequence Alignment/Map format and SAMtools, Genome Project Data Processing, vol.25, pp.2078-2079, 2009.

H. Linne, H. Yasaei, A. Marriott, A. Harvey, K. Mokbel et al., Functional role of SETD2, BAP1, PARP-3 and PBRM1 candidate genes on the regulation of hTERT gene expression, Oncotarget, vol.8, pp.61890-61900, 2017.

V. M. Lu, A. Goyal, A. Lee, M. Jentoft, A. Quinones-hinojosa et al., The prognostic significance of TERT promoter mutations in meningioma: a systematic review and meta-analysis, J Neurooncol, vol.142, pp.1-10, 2019.

A. Mayakonda, D. C. Lin, Y. Assenov, C. Plass, and H. P. Koeffler, Maftools: efficient and comprehensive analysis of somatic variants in cancer, Genome Res, vol.28, pp.1747-1756, 2018.

M. Meerang, K. Berard, M. Friess, B. K. Bitanihirwe, A. Soltermann et al., Low Merlin expression and high Survivin labeling index are indicators for poor prognosis in patients with malignant pleural mesothelioma, Mol Oncol, vol.10, pp.1255-1265, 2016.

V. Panou, M. Gadiraju, A. Wolin, C. M. Weipert, E. Skarda et al., Frequency of Germline Mutations in Cancer Susceptibility Genes in Malignant Mesothelioma, J Clin Oncol, vol.36, pp.2863-2871, 2018.

S. Pastorino, Y. Yoshikawa, H. I. Pass, M. Emi, M. Nasu et al., A Subset of Mesotheliomas With Improved Survival Occurring in Carriers of BAP1 and Other Germline Mutations, J Clin Oncol. JCO2018790352, 2018.

A. Pestana, J. Vinagre, M. Sobrinho-simoes, and P. Soares, TERT biology and function in cancer: beyond immortalisation, J Mol Endocrinol, vol.58, pp.129-146, 2017.

A. H. Ramos, L. Lichtenstein, M. Gupta, M. S. Lawrence, T. J. Pugh et al., Oncotator: cancer variant annotation tool, Hum Mutat, vol.36, pp.2423-2429, 2015.

T. Sato and Y. Sekido, NF2/Merlin Inactivation and Potential Therapeutic Targets in Mesothelioma, Int J Mol Sci, vol.19, p.988, 2018.

R. J. Sullivan, J. R. Infante, F. Janku, D. J. Wong, J. A. Sosman et al., First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study, Cancer Discov, vol.8, pp.184-195, 2018.

A. Tallet, J. C. Nault, A. Renier, I. Hysi, F. Galateau-salle et al., Overexpression and promoter mutation of the TERT gene in malignant pleural mesothelioma, Oncogene, vol.33, pp.3748-3752, 2014.
URL : https://hal.archives-ouvertes.fr/inserm-02478602

J. G. Tate, S. Bamford, H. C. Jubb, Z. Sondka, D. M. Beare et al., COSMIC: the Catalogue Of Somatic Mutations In Cancer, Nucleic Acids Res, vol.47, pp.941-947, 2019.

R. Tranchant, L. Quetel, A. Tallet, C. Meiller, A. Renier et al., Co-occurring mutations of tumor suppressor genes, LATS2 and NF2, in malignant pleural mesothelioma, Clin Cancer Res, vol.23, pp.3191-3202, 2017.
URL : https://hal.archives-ouvertes.fr/inserm-02478604

A. Untergasser, I. Cutcutache, T. Koressaar, J. Ye, B. C. Faircloth et al., Primer3--new capabilities and interfaces, Nucleic Acids Res, vol.40, p.115, 2012.

S. Walpole, A. L. Pritchard, C. M. Cebulla, R. Pilarski, M. Stautberg et al., Comprehensive Study of the Clinical Phenotype of Germline BAP1 Variant-Carrying Families Worldwide, J Natl Cancer Inst, vol.110, pp.1328-1341, 2018.

K. Wang, M. Li, and H. Hakonarson, ANNOVAR: functional annotation of genetic variants from highthroughput sequencing data, Nucleic Acids Res, vol.38, p.164, 2010.

Y. Yoshikawa, M. Emi, T. Hashimoto-tamaoki, M. Ohmuraya, A. Sato et al., High-density array-CGH with targeted NGS unmask multiple noncontiguous minute deletions on chromosome 3p21 in mesothelioma, Proc Natl Acad Sci U S A, vol.113, pp.13432-13437, 2016.

Y. Yoshikawa, A. Sato, T. Tsujimura, T. Otsuki, K. Fukuoka et al., Biallelic germline and somatic mutations in malignant mesothelioma: multiple mutations in transcription regulators including mSWI/SNF genes, Int J Cancer, vol.136, pp.560-571, 2015.

L. Zeng, A. Buard, I. Monnet, C. Boutin, J. Fleury et al., In vitro effects of recombinant human interferon gamma on human mesothelioma cell lines, Int J Cancer, vol.55, pp.515-520, 1993.